Oncotelic Therapeutics Inc (OTLC)

$0.07 0.00 (-2.40%)
Market Cap 29.48M
Revenue (ttm) 0.00
Net Income (ttm) -4.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.72
Volume 283,300
Avg Vol 138,156
Day's Range N/A - N/A
Shares Out 442.60M
Stochastic %K 0%
Beta -0.66
Analysts Strong Buy
Price Target $4.00

Company Profile

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatme...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 635 7000
Fax: 650 635 7001
Address:
29397 Agoura Road, Suite 107, Agoura Hills, United States
NetworkNewsWire
NetworkNewsWire Apr. 24 at 3:29 PM
NetworkNewsBreaks – $OTLC Featured in NetworkNewsAudio Editorial on Pipeline-Driven Valuation https://nnw.fm/42BlH
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 24 at 3:29 PM
BioMedNewsBreaks — $OTLC Highlights Partnership Strategy to Advance Pipeline https://ibn.fm/gX9eb
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 23 at 3:29 PM
BioMedNewsBreaks — $OTLC Featured In BioMedWire Editorial On Biotech Valuation Shift https://ibn.fm/JimL6
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 22 at 2:02 PM
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition $OTLC $AUTL $WVE $IOBTQ $RHHBY https://ibn.fm/4yuU5
0 · Reply
InvitationW
InvitationW Apr. 21 at 1:30 PM
$OTLC — Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution https://finance.yahoo.com/sectors/healthcare/articles/oncotelic-therapeutics-inc-otcqb-otlc-123000359.html
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 20 at 7:42 PM
BioMedNewsBreaks — $OTLC Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation https://ibn.fm/nYCMG
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 20 at 1:32 PM
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech $OTLC $SRPT $ALNY $ARCT $DNLI https://ibn.fm/uOEoD
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 16 at 6:48 PM
$OTLC Expands Beyond Biotech Through AI-Robotics Pivot, Unlocking New Value in GMP Automation https://ibn.fm/2An9k
0 · Reply
ckruel
ckruel Apr. 16 at 4:15 PM
$OTLC On April 16, 2026, Oncotelic Therapeutics reported financial results for the year ended December 31, 2025, posting net income of about $249 million versus a $4.8 million loss in 2024, largely due to a non-cash $365.4 million uplift in the fair value of its GMP Bio joint venture investment, which also created a sizable deferred tax liability. The year was described as transformational, marked by progress across its JV pipeline, expansion of its PDAOAI research platform, and continued operation of its San Diego GMP manufacturing facility.
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 16 at 1:55 PM
BioMedNewsBreaks — $OTLC Reports FY 2025 Net Income of $249 Million https://ibn.fm/FciEs
0 · Reply
Latest News on OTLC
No data available.
NetworkNewsWire
NetworkNewsWire Apr. 24 at 3:29 PM
NetworkNewsBreaks – $OTLC Featured in NetworkNewsAudio Editorial on Pipeline-Driven Valuation https://nnw.fm/42BlH
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 24 at 3:29 PM
BioMedNewsBreaks — $OTLC Highlights Partnership Strategy to Advance Pipeline https://ibn.fm/gX9eb
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 23 at 3:29 PM
BioMedNewsBreaks — $OTLC Featured In BioMedWire Editorial On Biotech Valuation Shift https://ibn.fm/JimL6
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 22 at 2:02 PM
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition $OTLC $AUTL $WVE $IOBTQ $RHHBY https://ibn.fm/4yuU5
0 · Reply
InvitationW
InvitationW Apr. 21 at 1:30 PM
$OTLC — Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution https://finance.yahoo.com/sectors/healthcare/articles/oncotelic-therapeutics-inc-otcqb-otlc-123000359.html
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 20 at 7:42 PM
BioMedNewsBreaks — $OTLC Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation https://ibn.fm/nYCMG
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 20 at 1:32 PM
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech $OTLC $SRPT $ALNY $ARCT $DNLI https://ibn.fm/uOEoD
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 16 at 6:48 PM
$OTLC Expands Beyond Biotech Through AI-Robotics Pivot, Unlocking New Value in GMP Automation https://ibn.fm/2An9k
0 · Reply
ckruel
ckruel Apr. 16 at 4:15 PM
$OTLC On April 16, 2026, Oncotelic Therapeutics reported financial results for the year ended December 31, 2025, posting net income of about $249 million versus a $4.8 million loss in 2024, largely due to a non-cash $365.4 million uplift in the fair value of its GMP Bio joint venture investment, which also created a sizable deferred tax liability. The year was described as transformational, marked by progress across its JV pipeline, expansion of its PDAOAI research platform, and continued operation of its San Diego GMP manufacturing facility.
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 16 at 1:55 PM
BioMedNewsBreaks — $OTLC Reports FY 2025 Net Income of $249 Million https://ibn.fm/FciEs
0 · Reply
IsaacP2
IsaacP2 Apr. 16 at 1:30 PM
$OTLC — Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress https://finance.yahoo.com/sectors/healthcare/articles/oncotelic-therapeutics-reports-fy-2025-123000619.html
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 10 at 5:22 PM
BioMedNewsBreaks – $OTLC Featured In AINewsWire Editorial On AI-Driven Pharma Manufacturing https://ibn.fm/ejxwx
0 · Reply
MonsterSuccess
MonsterSuccess Apr. 10 at 1:36 PM
$OTLC "Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space" https://ca.finance.yahoo.com/news/oncotelic-therapeutics-inc-otcqb-otlc-123000324.html
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 9 at 4:54 PM
AINewsBreaks – $OTLC Featured In Editorial On AI-Driven Transformation of Pharmaceutical Manufacturing https://ibn.fm/mZGrY
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 9 at 1:13 PM
AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages $OTLC $ROK $EMR $TMO $DHR https://ibn.fm/y16zF
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 8 at 7:38 PM
From Big Data to Better Drugs: How AI-Driven Platforms Are Changing Cancer Research $OTLC https://ibn.fm/bxtKs
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 8 at 4:20 PM
AINewsBreaks – $OTLC Featured in AINewsWire Editorial on AI-Driven Pharma Compliance https://ibn.fm/BesOp
0 · Reply
ckruel
ckruel Apr. 8 at 1:09 PM
$OTLC cont’d As regulatory expectations intensify and manufacturing complexity grows, pharmaceutical companies are moving beyond traditional quality systems toward a new paradigm: embedding artificial intelligence (AI) directly into operations as a real-time compliance layer. Rather than relying on retrospective audits and manual oversight, AI-driven systems now continuously monitor, validate and optimize production processes to align with evolving Good Manufacturing Practice (GMP) standards. This structural shift is increasingly visible across the industry and aligns with companies such as Oncotelic Therapeutics Inc., which operate at the intersection of life sciences and advanced digital technologies, reflecting the broader movement toward intelligent, automated compliance frameworks
0 · Reply
ckruel
ckruel Apr. 8 at 1:08 PM
$OTLC Oncotelic Therapeutics Inc. (OTCQB: OTLC) Operates at Intersection of Life Sciences, Advanced Digital Technologies, NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- via AINewsWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by AINewsWire ("AINW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory Standards,” please visit https://ainewswire.com/ai-driven-compliance-gamechanger-in-pharma-manufacturing-and-regulatory-standards/. .
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 7 at 1:37 PM
AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory Standards $OTLC $NVDA $AMZN $HON $OMCL https://ibn.fm/t6O0q
0 · Reply
dransomstocks
dransomstocks Apr. 7 at 9:47 AM
$NGTF Nightfoods Holdings, Inc. AKA TechForce Robotics is now in an agreement with Oncotelic Therapeutics, Inc. ($OTLC) . The press release said, “This strategic collaboration brings together TechForce Robotics’ advanced robotics engineering capabilities with Oncotelic’s proprietary AI-Enhanced technologies to jointly develop and commercialize AI-Enhanced, GMP-compliant robotic systems designed for pharmaceutical manufacturing and laboratory automation environments.“ This sounds very exciting, from a long-term perpective. Revenues from using robotics in pharmaceutical manufacturing might be huge. Glad that the company managers, who are also the biggest shareholders, appear to be quite serious about making our investments profitable.
1 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 6 at 6:50 PM
TechMediaBreaks – $NGTF Enters Robotics And AI Biopharma Partnership With $OTLC https://ibn.fm/IbOJ0
0 · Reply